# Telix Pharmaceuticals Limited (TLX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.03, market value $3.1 billion.

## Valuation
- **P/E (trailing): 90.3×** (5-yr avg 157.8×, 3-yr avg 157.8×). Telix Pharmaceuticals Limited trades at 90.3× trailing earnings, well below its own five-year average of 157.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 3.8×**. Each dollar of revenue is priced at 3.8×.
- **Price / book: 6.3×**. The shares trade at 6.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 65.0×**. Enterprise value is 65.0× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: -1.4%** (5-yr avg -0.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 1.1%**. The inverse of the P/E: 1.1% of the price is earned each year.

## Profitability
- **Gross margin: 53.1%**. Telix Pharmaceuticals Limited keeps 53.1% of revenue after the direct cost of what it sells.
- **Operating margin: 3.7%**. 3.7% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -0.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -1.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 4.4%**. Return on all capital, debt included, is 4.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -0.6%**. Each dollar of assets produces -0.6% of profit.

## Growth
- **Revenue growth (1 yr): 55.6%**. Revenue grew 55.6% over the last year.
- **EPS growth (1 yr): -121.6%**. Earnings per share fell 121.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.98**. Debt is 0.98 times equity, moderate leverage.
- **Net debt / EBITDA: 5.1×**. It would take 5.1 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: 164.5×**. Operating profit covers interest 164.5× over, a safe margin.
- **Current ratio: 1.43** (quick 1.43). Current assets cover the next year's liabilities 1.43 times.
- **Altman Z-score: 3.84**. A Z-score of 3.84 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Telix Pharmaceuticals Limited does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover Telix Pharmaceuticals Limited; the consensus is strong_buy, with an average price target of $20.52 (+127% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -15.1%** (YTD 20.8%, 3-mo -9.7%). The shares are down 15.1% over twelve months including dividends.
- **From 52-week high: -31.1%** (43.8% above the low). Trading 31% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 35**. An RSI of 35 is neutral.
- **Beta (1 yr): 1.02** (volatility 56%). Beta of 1.02 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TLX · Page: https://foliofundamentals.com/stocks/tlx

Not investment advice.